Company
Biotheranostics, Inc.
Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology.
Also known as Biotheranostics
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Biotheranostics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology.
Funding snapshot
- Total raised
- $20MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $20M2016-01-20
Funding rounds
- Round, 2016
- $20M2016-01-20, SEC form D sold, 4 investors
About the company
- Status notes
- Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology.
Products
- Other
- BREAST CANCER INDEX
- Other
- CANCERTYPE ID
Exit
- Acquisition
- 2021-02
Loading relationship preview